Clinical trials are run on software from another era.
Every sponsor pays $500K to $1M per trial for platforms that still require CRAs to compare paper source documents by hand, surface adverse events after the fact, and stitch together data from eight disconnected vendors.
One operating system. The whole trial lifecycle.
wrldOS sits above the incumbent stack and reads from every CTMS, EDC, eTMF, IRT, and safety system you already run. It doesn't replace one tool. It replaces the seams between them.
Predictive, not reactive.
AI risk scoring delivers 48–72 hour early warnings on serious adverse events. Enrollment is forecast weeks ahead, not reported weeks behind. Protocol deviations surface themselves.
Incumbents report after the fact. wrldOS predicts before it matters.Unified, not fragmented.
Command Center consolidates signals from every vendor into one pane. The data you need to run a trial stops living in eight dashboards and thirty-seven daily emails.
Veeva is a document system. Medidata is an EDC. wrldOS is the layer that unifies them.AI-native, not bolted on.
Seven integrated ML engines, 120+ API endpoints, full 21 CFR Part 11 audit trail. Built to the FDA's April 2023 AI/ML guidance from day one — not retrofitted onto 2009 software.
The incumbents' AI is a press release. Ours is the architecture.The platform is real. The demo is live.
Not renderings. Not slides. A working front end powered by a production backend — 120+ endpoints, 30+ database tables, 7 ML engines. Walk through it like a sponsor's Chief Medical Officer would on a Monday morning.
Three forces converged. The window is open.
AI-native clinical trial infrastructure wasn't possible five years ago — and won't be uncontested five years from now. The moment is specific, and it is right now.
The FDA gave explicit permission.
The April 2023 AI/ML Discussion Paper stated plainly that FDA supports AI in drug development when appropriately validated. ICH E6(R3) now expects risk-based monitoring, not optional analytics. The “will regulators accept it” excuse is gone.
FDA 2023 · ICH E6(R3) DraftBiotech funding collapsed 52%.
Sponsors that treated trial software as discretionary now treat it as material to runway. Cutting $700K–$1.9M per trial extends runway by months that matter to whether the program reaches its next milestone.
SVB Healthcare 2024 · BioPharma DiveThe stack is production-ready.
Large language models, ensemble OCR at 95%+ accuracy, mature anomaly detection, HIPAA-compliant cloud. What required $1M and a specialized team to build in 2020 is developer-accessible and deployable now.
Built by Kelechi Owunwanne — a Clinical Research Associate and operator-founder who came up across global, mid-size, and specialty CROs. He saw the same structural patterns at every scale, and built what replaces them.
That range matters. Site initiation visits, monitoring visits, close-outs — across multiple operating models, on CTMS, EDC, eTMF, IRT, and safety platforms from every major vendor. He saw the same structural patterns at every scale, and built what replaces them.